No Detail Found!

Sustained virological response (SVR) and safety of two direct acting anti-viral (DAA) combination therapies in chronic hepatitis-c infected patients of lahore, pakistan. A randomized controlled trial

Author(s)
Salman Kazmi Mayo hospital, Lahore, Pakistan
Humaira Farooqi Pathology Department, King Edward Medical University, Lahore, Pakistan
Umer Sohail Mayo hospital, Lahore, Pakistan
Sohaib Haider Zaidi Endocrinology Department, Services Hospital, Lahore, Pakistan
Naeem Majeed United Nations International Children's Emergency Fund (UNICEF), Lahore, Pakistan
Safia Firdous Faculty of Rehabilitation Sciences and Allied Health Sciences (FRAHS), Riphah International University, Lahore, Pakistan
Abstract
Chronic Hepatitis C (HCV) is a deadly infection affecting > 185 million people worldwide and led to liver cirrhosis, hepatocellular carcinoma, or liver failure. Recently, treatment regimens of chronic HCV have entered the era of direct acting anti-virals (DAAs). Sustained virological response (SVR) rate is one of the best available tools to evaluate the e??cacy of DAA treatments. Objective: To compare SVR rate and safety of two combinations of DAA treatments (Sofosbuvir and Daclatasvir vs Sofosbuvir and Velpatasvir) in chronic HCV infected patients of Lahore, Pakistan. Methods: Present randomized controlled trial was conducted at Mayo Hospital, Lahore, Pakistan and recruited 76 chronic HCV infected patients according to Consort guidelines. Registered patients were allocated in two groups by lottery method. Group A received sofobuvir with daclatasvir (SOFO + DCV) while group B received sofobuvir with velpatasvir (SOFO + VEL) treatment for 12 weeks. Response to therapy was evaluated in terms of SVR after 24 weeks and safety pro??le of the drug. Results: Both treatment groups showed high SVR 24 weeks after the completion of therapy. Group A (SOFO + DCV) presented 92% SVR while group B showed 97% SVR rate. Both DAA combination therapies presented good e??cacy and safety pro??le. Few contraindications noted during the treatment included fatigue, arthritis, headache, loss of appetite and anemia. Conclusions: The e??cacy of both DAA combination therapies was comparably high with > 90% SVR rate. Group A proved safer as compared to group B. Studied DAA combinations are effective treatment options for chronic HCV treatment planning.
Publication Details
Page(s) 136-139
Published Journal: Pakistan Journal of Health Sciences, Volume: 3, Issue: 6, Year: 2022

Request the full text from PASTIC

Keywords
Chronic HCV, sustained virological response (SVR), Direct Acting Anti-Virals (DAA), Sofobuvir
0

Citations

0

Downloads

36

Views